Metabolomics @ UniCa
Since 2008, metabolomics (one of the youngest “-omics”) has been the major interest of the group. Carrying out metabolomic analyses, and collaborating with different clinicians such as neonatologists, neurologists, cardiologists, oncologists, forensic doctors, we are trying to better understand the metabolic changes in biofluids and tissues for identifying new biomarkers of diseases, predict the prognosis and the response to the therapy. A better understanding of the role of metabolites changes in physiophatological conditions might lead to a new tailored medicine.
Main pathological conditions under investigations are: neonatal hypoxia, multiple sclerosis, epilepsy, amyotrophic lateral sclerosis, heart failure, time from death, cancer, chronic inflammatory bowel disease. To address these, we are developing analytical chemistry techniques, by using NMR spectroscopy and mass spectrometry, and innovative statistical approaches.
The working environment includes medical doctors, biologists, chemists, pharmaceutical chemists and mathematicians.
The Metabolomics Group is also involved in the designing of database tools for metabolomics.